Mario R. Velasco

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

Andrew L. Himelstein, Jared C. Foster, James Khatcheressian et al. · JAMA · 2017 · 357 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Mikkael A. Sekeres, Megan Othus, Alan F. List et al. · Journal of Clinical Oncology · 2017 · 238 citations

Medicine, Oncology, Pharmacotherapy +15

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein et al. · Journal of Clinical Oncology · 2021 · 220 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive‐stage small cell lung cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E1508)

Chandra P. Belani, Suzanne E. Dahlberg, Charles M. Rudin et al. · Cancer · 2016 · 68 citations

Medicine, Oncology, Pharmacology +16

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

Anne S. Tsao, Jieling Miao, Ignacio I. Wistuba et al. · Journal of Clinical Oncology · 2019 · 50 citations

Medicine, Oncology, Pharmacology +14